Quince Therapeutics, Inc. announced the completion of enrollment in its pivotal Phase 3 NEAT clinical trial. This trial is evaluating the company's lead asset, eDSP, for the treatment of the rare neurodegenerative disease Ataxia-Telangiectasia (A-T).
Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, stated that completing enrollment is a major milestone, bringing the company one step closer to advancing a first-to-market treatment for A-T. The trial enrolled 78 participants in the six to nine year-old primary analysis population and 21 participants aged 10 years or older.
Quince remains on track to deliver topline results in the first quarter of 2026. Assuming positive results from the NEAT trial, the company plans to submit applications for regulatory approval in the U.S. and Europe in the second half of 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.